MA
CRSP icon

MCF Advisors’s CRISPR Therapeutics CRSP Stock Holding History

MCF Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104K Hold
2,187
– – ﹤0.01% 493
2025
Q4 		$115K Buy
2,187
+150
+7% +$8.98K 0.01% 384
2025
Q3 		$132K Hold
2,037
– – 0.01% 302
2025
Q2 		$99.1K Hold
2,037
– – 0.01% 310
2025
Q1 		$69.3K Hold
2,037
– – 0.01% 357
2024
Q4 		$80.2K Buy
+2,037
New +$96.2K 0.01% 342
2024
Q2 		– Sell
-20
Closed -$1.36K – 1036
2024
Q1 		$1.36K Buy
+20
New +$1.43K ﹤0.01% 851

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MCF Advisors's CRSP Position: Q1 2026 in Review

MCF Advisors held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 2,187 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #493.

MCF Advisors first reported a position in CRSP in Q1 2024 and has held it in 7 quarters since. The position peaked at $132K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • MCF Advisors held 2,187 shares of CRISPR Therapeutics worth $104K as of Q1 2026.
  • MCF Advisors left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of MCF Advisors's portfolio in Q1 2026, its #493 holding.
  • MCF Advisors first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • MCF Advisors's CRISPR Therapeutics position peaked at $132K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on MCF Advisors's 13F filing for Q1 2026, filed 11 May 2026.